Repligen | RGEN - 销售收入



金融业
股票价格
USD
资产
USD 2.95B
现金及等价物
USD 606.78M
销售成本
USD 94.09M
流动资产
USD 1.2B
流动负债
USD 132.66M
债务
USD 690.94M
EBIT
USD 21.13M
EBITDA
USD 43.77M
员工
1.78K
EPS每股收益
USD 0.54
股本和储备
USD 2.11B
销售毛利
USD 110.04M
债务利息支出
USD 5.66M
利息收入
USD 7.31M
贷款资金
USD 551.05M
市值
USD 9.26B
净收入
USD 5.01M
营业费用
USD 183M
营业利润
USD 21.13M
普通股股本
USD 56.43M
PE价格收益
105.09
税前利润
USD 14.15M
销售收入
USD 204M
销售和管理费用
USD 76.62M
股票
USD 186.6M
贸易债权人
USD 33.23M
应收帐款人
USD 157.71M


销售 更改 日
Agilent USD 1.84B 37M 2026-03
Align Technology USD 1.06B 20M 2026-06
Bio Techne USD 321.2M 9.8M 2026-06
BioMarin Pharmaceutical USD 990M 224M 2026-06
Bristol-Myers Squibb USD 12.97B 1.48B 2026-06
Bruker USD 838.5M 15.1M 2026-06
Charles River Laboratories USD 1000M 4.2M 2026-06
Danaher USD 6.3B 350M 2026-06
Dentsply International USD 898M 18M 2026-06
General Electric Aerospace USD 12.63B 1.03B 2026-06
Henry Schein USD 3.46B 90M 2026-06
Illumina USD 1.16B 70M 2026-06
IQVIA Holdings USD 4.37B 220M 2026-06
Mettler Toledo International USD 1.03B 82.87M 2026-06
Myriad Genetics USD 190.7M 9.7M 2026-06
OraSure Technologies USD 26.76M 322K 2025-12
Pacific Biosciences Of California USD 44.64M 6.2M 2025-12
Pfizer USD 15.03B 530M 2026-06
Repligen USD 204M 10M 2026-06
Revvity USD 729.68M 18.68M 2026-06
Standard Biotools USD 21.1M 2.7M 2026-03
Thermo Fisher Scientific USD 11.99B 980M 2026-06
Waters USD 1.64B 370M 2026-06
West Pharmaceutical Services USD 872.3M 27.4M 2026-06